Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Through the generous support of Regeneron, four times a year River Journal publishes the on-site report of a high school ...

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that has recurred in patients who had ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

This was the stock's fourth consecutive day of gains.

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...